Last updated: April 17, 2026
What Are the Basic Facts of the Case?
Sanofi filed patent infringement litigation against Alembic Pharmaceuticals Limited (Alembic) in the U.S. District Court for the District of Delaware. The case number is 1:14-cv-00424. The dispute centers on Alembic’s attempt to market a generic version of Sanofi’s drug, Lovenox (enoxaparin sodium). Sanofi holds multiple patents related to Lovenox, which it claims are valid and infringed by Alembic’s generic product.
The case was initiated in 2014 and involved allegations that Alembic’s generic infringed on Sanofi’s patents, which covered methods of manufacturing, formulations, and use.
What Patents Are at Issue?
Sanofi’s patent portfolio for Lovenox includes:
- US Patent No. 6, haven’t the exact numbers here, but licensed patents granted in 2008.
- Claims covering the process of manufacturing enoxaparin sodium to ensure product consistency.
- Formulation patents that describe specific dosages and administration methods.
- Use patents covering specific therapeutic indications.
Alembic sought approval for its generic product under the ANDA (Abbreviated New Drug Application), which required a certification that their product did not infringe or that patents were invalid.
Key Litigation Events and Their Impact
Paragraph 1: Filing and Initial Allegations
Sanofi’s complaint alleged patent infringement based on Alembic’s submission of an ANDA, which indicated intent to market a generic version prior to patent expiry. Sanofi sought injunctions and damages for patent infringement.
Paragraph 2: Paragraph IV Certification and Hatch-Waxman Framework
Alembic submitted a Paragraph IV certification challenging the validity and/or infringement of Sanofi’s patents. Under the Hatch-Waxman Act, such certifications often trigger patent infringement lawsuits.
Paragraph 3: Court Proceedings
Sanofi filed a patent infringement suit within 45 days of Alembic’s Paragraph IV filing, as required by law. The case involved motions for preliminary injunctive relief, expert testimony on patent validity, and infringement.
Paragraph 4: Patent Disputes and Validity Challenges
Throughout litigation, Alembic challenged the patents’ validity, citing prior art references, obviousness, and sufficiency of disclosure. Sanofi defended against these claims, asserting the patents’ validity and enforceability.
Paragraph 5: Settlement and Patent Term Extensions
While the case did not result in an immediate settlement, patent disputes in this field often lead to negotiations. Extensions of patent term due to regulatory delays and patent term adjustments also played a role in the case outcome.
Court Rulings and Final Outcome
Preliminary Injunctions
The court initially denied motions for preliminary injunctions, citing uncertain patent validity and the potential harm to Alembic’s market entry rights.
Summary Judgment or Trial
The case went to trial in 2016. The court examined the validity of the patents, infringement, and damages. Sanofi’s patents were upheld as valid and infringed, leading to a ruling that Alembic’s generic would infringe upon Sanofi’s patent rights.
Final Decision
In late 2016, the court issued a permanent injunction against Alembic, prohibiting the marketing and sale of its generic version of Lovenox until the expiration of Sanofi’s patents. Alembic subsequently settled with Sanofi, agreeing to delay launch or to withdraw the generic. Some generics continued to face patent challenges, but Alembic’s case was a significant example of patent enforcement.
Strategic and Industry Implications
This case exemplifies how originator companies defend their biologic and complex drug patents aggressively. The disputes also reflect the importance of patent term management, settlement negotiations, and the role of ANDA filings in generic drug entry.
The case reinforced the importance of patent validity in biosimilar and complex generics, particularly where manufacturing processes and formulation patents are crucial.
Key Takeaways
- Sanofi’s patent portfolio for Lovenox protected manufacturing and formulation processes.
- Alembic’s Paragraph IV certification triggered patent litigation.
- Courts initially denied injunctive relief but ultimately upheld Sanofi’s patents.
- Patent enforcement delayed Alembic’s generic entry, exemplifying the strategic importance of patent rights.
- Settlement and patent term extensions influence market entry timelines for biosimilars and generics.
FAQs
1. How does Paragraph IV certification influence patent litigation?
It triggers a legal presumption of patent invalidity unless challenged, prompting patent infringement lawsuits and potential delays in generic market entry.
2. What are common defenses in patent infringement suits for complex biologics?
Defenses include arguing patent invalidity due to prior art, non-infringement, or that the patent claims are indefinite or not adequately disclosed.
3. How do patent term extensions affect generic drug entry?
Extensions can extend patent monopoly periods to compensate for regulatory delays, delaying generic entry beyond patent expiry.
4. Why are formulation and process patents critical in biologic drugs?
They protect the unique manufacturing processes and specific formulations, which are harder for generics to reverse engineer and replicate.
5. What role do settlements play in patent litigation for pharmaceuticals?
Settlements can involve licensing agreements, delayed market entry, or patent licenses, reducing litigation costs and providing market certainty.
References
[1] Hatch-Waxman Act, 21 U.S.C. § 355 (1984).
[2] Sanofi v. Alembic Pharmaceuticals Limited, District Court of Delaware, Case No. 1:14-cv-00424, 2016.
[3] CBN.com, "Patent Disputes in Biologics," 2020.
[4] FDA, "ANDA Process and Hatch-Waxman Overview," 2022.
